FDA - Spark Newswire

2 minute read

FDA
News

BioSig Says Co’s Signal Processing Technology For Electrophysiology To Be Featured During 2021 Stanford Biodesign New Arrhythmia Technologies Retreat

Today, 3:26 PM

BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and

BSGM

1 minute read

FDA
News

AstraZeneca Says Vaxzervia Induced Immunity For At Least 1 Year Following A Single Dose And Strong Immune Responses Following Either A Late Second Dose Or Third Dose

By Benzinga Newsdesk

Today, 3:26 PM

-Reuters

AZN

5 minute read

FDA
News

CEL-SCI Says Co’s Multikine Immunotherapy Produces 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) In The Group Receiving Surgery Plus Radiotherapy In Head And Neck Cancer Phase 3 Study

By Benzinga Newsdesk

Today, 3:26 PM

CEL-SCI Corporation (NYSE:CVM) today announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine® (Leukocyte Interleukin, Injection)* in the treatment of advanced (stages

CVM

2 minute read

FDA
News

Aytu BioPharma Announces Peer-Reviewed Publication Of Clinical Results From Healight(TM) Pilot Study

By Benzinga Newsdesk

Today, 3:26 PM

Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from the first in-human, open label,

AYTU

2 minute read

FDA
News

AbbVie Says Co’s Gastroenterology Pipeline To Be Featured At 16th Congress Of European Crohn’s And Colitis Organisation

By Benzinga Newsdesk

Today, 3:26 PM

AbbVie today announced new data on upadacitinib (RINVOQ®) in ulcerative colitis and risankizumab (SKYRIZI®) in Crohn's disease will be presented as oral presentations at the 16th Congress of European

ABBV

1 minute read

Catalyst Biosciences Stock Moves Higher On Additional FDA Fast Track Tag For MarzAA

By Vandana Singh

Today, 3:26 PM

The FDA has granted Fast Track Designation to Catalyst Biosciences Inc’s (NASDAQ:CBIO) Marzeptacog alfa (activated), MarzAA, the Company’s subcutaneously administered next-generation engineered…

CBIO

4 minute read

FDA
News

ShockWave Medical Says Publications Validate Clinical Safety And Efficacy Of Shockwave Intravascular Lithotripsy

By Benzinga Newsdesk

Today, 3:26 PM

Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the safety, efficacy and mechanism of

SWAV

3 minute read

Gilead’s Kite Announces Yescarta CAR T-cell Therapy Improved Event-Free Survival By 60% Over Chemotherapy Plus Stem Cell Transplant In Second-Line Relapsed Or Refractory Large B-cell Lymphoma

By Bill Haddad

Today, 3:26 PM

-- Landmark ZUMA-7 Study was Initiated in 2017 as the First Randomized Clinical Trial to Test the Earlier Use of a CAR T-cell Therapy Against Standard of Care -- -- Study Met the Primary and Key Secondary

GILD

1 minute read

FDA
News

Veru Announces Presentation Of Phase 1b/2 Clinical Study Update For Sabizabulin (VERU-111) In Men With Metastatic Castration Resistant Prostate Cancer At The 2021 European Association Of Urology Annual Congress

By Benzinga Newsdesk

Today, 3:26 PM

Veru Inc. (NASDAQ:VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, today announced updated clinical results from the ongoing Phase

VERU

3 minute read

Onconova Therapeutics Provides Update Oh Phase 1/2 Trial Of Rigosertib-Nivolumab Combination; Says Expansion Of Trial Underway At Highest Dose

By Bill Haddad

Today, 3:26 PM

Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration Preliminary data support the preclinical observation of rigosertib augmenting the response to

ONTX